Previous 10 | Next 10 |
Gainers: Immunome (IMNM) +93%, Avinger (AVGR) +33%, Titan Pharmaceuticals (TTNP) +17%, GBS (GBS) +15%, VistaGen Therapeutics (VTGN) +15%.Losers: MEDNAX (MD) -23%, ReWalk Robotics (RWLK) -21%, Shineco (TYHT) -19%,&...
Greenland Technologies Holding Corporation (GTEC) +186% on signing co-operation agreement with SOCMA.Immunome (IMNM) +152% on discovery of antibodies neutralizing SARS-CoV-2 variants.Avinger (AVGR) +57%.Heritage Global (HGBL) +42%.U.S. Well Services (USWS) +35%.Cleveland BioLabs (CB...
Vistagen Therapeutics (VTGN) jumps 13% premarket after Jefferies initiated coverage with a Buy rating and price target of $6.Analyst Andrew Tsai says that company's lead asset, PH94B, a fast-acting nasal spray had compelling Phase II data and could become the first FDA-approved trea...
VistaGen Therapeutics (VTGN): Q3 GAAP EPS of -$0.07 misses by $0.02.Revenue of $0.31M beats by $0.14M.Press Release For further details see: VistaGen Therapeutics EPS misses by $0.02, beats on revenue
Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD) Strengthened Balance Sheet upon closing of $100 million underwritten public ...
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a generation of novel medicines for anxiety, depression, and other central nervous system disorders, primarily through nasal sprays. VistaGen has three therapeutics in their pipeline across...
VistaGen Therapeutics (VTGN) has received a notice from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing.The company is now in full compliance with all applicable listing standards, and Nasdaq considers the matter closed. For further detail...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central...
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics , Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other ce...
Penny Stocks With Big Price Targets Whether you’re looking for penny stocks to buy on Robinhood, ETrade, TD, Webull, Interactive Brokers, or other platforms, everyone has 1 goal. At least I would hope everyone has one goal, which is to make money. One of the interesting p...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...